Skip to content
Business
Prognosis

Pfizer's Grip on Paxlovid Thwarts Research on Covid Treatment

  • Resistance to solo therapy a ‘matter of time,’ chemist says
  • Drug giant rebuffs outside requests for supplies for trials
Pfizer Inc. Paxlovid Covid-19 pill production.

Pfizer Inc. Paxlovid Covid-19 pill production.

Source: thomas hansmann.fotograf

Pfizer Inc. is resisting requests for study supplies of its Covid-19 pill, Paxlovid, disappointing researchers who say combining the $22 billion therapy with other drugs might stave off resistance. 

Pfizer hasn’t started any combination trials in people, and a review of the clinicaltrials.gov database shows no outpatient studies combining Paxlovid, the mainstay US Covid therapy, with other antiviral drugs or antibodies. Some academic researchers and advocacy groups say they can’t get Paxlovid for human studies that could maintain or improve its effectiveness and expand use.